A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Trial details
- Registry ID
- NCT06868628
- Drugs studied
- Foralumab Nasal
TrialRedline tracks 4 clinical trials sponsored by Tiziana Life Sciences LTD: 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)NCT06868628 | Foralumab Nasal | Recruiting | 2027-04-01Estimated |
| Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple SclerosisNCT06890923 | Foralumab TZLS-401 100 µg | Recruiting | 2026-04-30Estimated |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal ForalumabNCT07688239 | Foralumab Nasal | Enrolling by invitation | 2027-07Estimated |
| A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsNCT06292923 | Foralumab | Completed | 2026-09-17Actual |
Names as written in the registry records.
NCT06292923 · Tiziana Life Sciences LTD
Before: Estimated. After: Actual.
Before: Estimated. After: Actual.
Before: Sep 2026. After: 17 Sep 2026.
Before: Active not recruiting. After: Completed.
NCT07688239 · Tiziana Life Sciences LTD
Before: Not yet recruiting. After: Enrolling by invitation.
NCT06292923 · Tiziana Life Sciences LTD
Before: Nov 2025. After: Sep 2026.
Before: Recruiting. After: Active not recruiting.